Introduction {#s1}
============

Idiopathic nephrotic syndrome (NS) is a relatively common disease of childhood, and the most frequent glomerular disease in children ([@B18]). NS is characterized by nephrotic range proteinuria (\> 50 mg/kg/die), hypoalbuminemia (serum albumin \< 2.5 g/dL), peripheral edema, and hyperlipidemia. The vast majority of NS patients are steroid-sensitive, with complete disease remission after steroid treatment, although many of them relapse. Approximately half of steroid-sensitive patients relapse many times per year, and nephrologists categorize them in "frequently relapsing" and "steroid-dependent". These patients are at major risk for chronic steroid-related side effects (i.e. metabolic, ocular and skeletal complications) and substantial morbidity ([@B8]; [@B21]). For this reason, a wide range of steroid sparing agents such as levamisole, cyclophosphamide, cyclosporine A, tacrolimus, mycophenolate mofetil, and rituximab have been proposed over time ([@B18]), the latter being successfully used as steroid sparing agent in idiopathic NS in the last decade ([@B20]; [@B11]).

Rituximab is a chimeric mouse/human monoclonal antibody produced through genetic engineering techniques with the structure of a IgG1 kappa immunoglobulin and an molecular weight of about 145 kD. The transmembrane antigen CD20, located on pre-B and mature B lymphocytes is the specific target of this monoclonal antibody, which is capable to lead to B cell lysis through apoptosis and different immune mechanisms, including antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. For this reason, rituximab is considered a key option to intervene upon B cells critical roles in inflammatory, such as cytokine production, antibodies production, antigen presentation, T-cells activation, proliferation and neoplastic processes, such as growth, anaplasia, and invasion. Specifically, rituximab is licensed for the treatment of a plenty of clinical conditions in adults and children, mainly neoplastic diseases, such as non-Hodgkin\'s lymphoma, chronic lymphocytic leukemia and inflammatory diseases, such as rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, pemphigus vulgaris. Rituximab is administered as an intravenous infusion by an experienced healthcare professional with a specific background and in a clinical environment appropriate to manage adverse reactions to the drug, with a potentially prompt access to resuscitation facilities. Premedication with antipyretic and diphenhydramine therapies should be always administered before the infusion \[Mabthera EPAR -- Product Information. European Medicines Agency (internet). Available from: <https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf>; Rituxan labelling. Food and Drug Administration. Available from: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/103705s5461lbl.pdf> -- cited 2020 Mar 01\]. A rich body of literature addressing acute and chronic adverse events following rituximab administration is available, also in the particular setting of idiopathic nephrotic syndrome ([@B16]). However, to our knowledge, this is the first report of acute hypokalemia with clinical manifestations after rituximab administration.

Case Report {#s2}
===========

A 4-year-old child of Moroccan origin, with non-consanguineous parents, was first diagnosed with idiopathic nephrotic syndrome in 2002. Since then, she was followed by the Nephrology Unit of the Meyer Children\'s University Hospital in Florence. Despite sensitive to steroid therapy, she soon developed prednisone dependence, and steroid sparing immunosuppressive drugs were administered ([**Figure 1**](#f1){ref-type="fig"}).

![Historical view of immunosuppressive treatment with a detail on rituximab administrations and subsequent relapses. PDN, prednisone; CPH, cyclophosphamide; CYA, cyclosporine A; MMF, mycophenolate mofetil; RTX, rituximab.](fphar-11-00915-g001){#f1}

However, steroid-free therapeutic regimen was hardly achieved, and the girl developed more than one steroid-related side effect; short stature, osteoporosis (vertebral collapse, with the need for a lumbosacral corset), infections (pneumonia) and gastrointestinal side effects were reported. For these reasons, the impossibility to wean from steroids, and the growing evidence in the literature, on March 2013, aged 15, she was started on rituximab, with a first intravenous infusion of 375mg/m^2^. Since then, she was able to rapidly taper and stop steroid therapy for almost one year. As expected ([@B22]), she experienced subsequent relapses, with the need for new rituximab administrations, approximately one per year ([**Figure 1**](#f1){ref-type="fig"}). From a retrospective review of clinical charts, no serious adverse events were ever reported following the monoclonal antibody administration. However, in two occasions, after rituximab administration in November 2016 and August 2017 (aged 18) the girl reported dizziness, hypotension and pre-syncopal symptoms, which were considered not clinically relevant.

On November 21, 2019, the girl was scheduled for her 6^th^ intravenous rituximab infusion (375mg/m^2^, total dose 500mg), in our Nephrology Unit, as an outpatient. Before starting the infusion, at 9am, a blood gas test was performed: her serum potassium level was 4.0 mmol/L ([**Figure 2**](#f2){ref-type="fig"})---sodium, calcium, magnesium, glucose, pH and bicarbonate levels were normal. After 3 hours from the beginning of the infusion the girl reported dizziness and palpitation, her heart rate increased from 60 to 100 bpm and the infusion was temporary stopped. At 4pm, about 7 hours from the beginning, the infusion was ended, but the girl was still symptomatic for tachycardia. A second blood gas test was then obtained, and potassium level was 2.3 mmol/L, with no significant changes in electrolytes, acid-base balance or other parameters. Hypokalemia was rapidly confirmed by a third blood gas analysis (2.4 mmol/L) and by the hospital central laboratory (2.5 mmol/L). An ECG was obtained reporting hypokalemia signs: normal sinus rhythm, HR 120 bpm, diffuse repolarization abnormalities, and not measurable QTc interval ([**Figure 2**](#f2){ref-type="fig"}). Intravenous potassium (total dose K^+^ = 20 mmol) was started and the patient admitted to the pediatric ward for overnight monitoring. At 9pm, less than 5 hours from the end of the infusion, her symptoms were completely resolved, and her potassium level was back in the normal range (3.9 mmol/L, hospital central laboratory). The next morning, without any other supplementation, serum potassium level was 3.6 mmol/L, and the day after 4.0 mmol/L. A second ECG obtained on November 22 showed complete reversion of ventricular abnormalities ([**Figure 2**](#f2){ref-type="fig"}). At follow-up the patient serum potassium levels were stably in the normal range.

![**(A)** Potassium levels (mmol/L) over time and potassium central laboratory normal value (3.3 mmol/L, dotted line). ECG before **(B)** and after **(C)** rituximab administration on November 21 and November 22, 2019.](fphar-11-00915-g002){#f2}

Discussion {#s3}
==========

Rituximab is a successful steroid sparing option in the case of idiopathic NS, given its action on B cells, that have recently been re-evaluated in the pathogenesis of this clinical condition ([@B5]; [@B16]). A wide range of data about adverse events associated with rituximab have been published, coming from clinical trials and post-marketing surveillance comprising patients with inflammatory or neoplastic diseases. Infusion-related adverse reactions are the most frequently observed events with clinical manifestations predominantly comprising fever, chills, asthenia, headache, anaphylaxis, anaphylactoid events, bronchospasm, respiratory distress, skin rash, urticaria, angioedema, or pruritus. These clinical manifestations are typically related to the first infusion and usually with an onset time of about 30-120 minutes. Given the rising use of monoclonal antibodies to treat several clinical conditions, a parallel increase in hypersensitivity reactions to these drugs have been recorded in the literature, including rituximab ([@B9]; [@B25]). They have been defined as belonging to different phenotypes associated to several endotypes: type I-like (IgE and non-IgE), cytokine release, mixed (type I-like and cytokine release) or type IV reactions ([@B12]). In the case of a confirmed IgE mediated reaction, desensitization with the drug, including rituximab, has demonstrated to be effective, safe and it is considered the first-line therapy in selected patients ([@B4]; [@B3]; [@B24]; [@B7]).

Early- and late-onset hypogammaglobulinemia, neutropenia, and infections, including bacterial, fungal and viral (new and reactivated) episodes, are also commonly reported in association with rituximab administration ([@B17]; [@B6]). Hyperglycemia and cardiovascular disorders (mostly arrhythmias, hypertension, and hypotension) are associated with the drug administration as well. In very rare cases, rituximab has been associated to progressive multifocal leukoencephalopathy \[Mabthera EPAR -- Product Information. European Medicines Agency (internet). Available from: <https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf>; Rituxan labelling. Food and Drug Administration. Available from: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/103705s5461lbl.pdf> -- cited 2020 Mar 01\].

Hypokalemia caused by rituximab administration has never been reported in the literature so far. Hypokalemia was reported as a rare adverse event of complex chemo-immunotherapy combinations for lymphoma treatment ([@B19]; [@B1]; [@B15]; [@B10]; [@B23]). However, none of these reports suggested a direct link between rituximab administration and hypokalemia. In particular, the addition of lenalidomide, everolimus, or vorinostat to classic R-CHOP (rituximab-cyclophosphamide, doxorubicin, vincristine, prednisone) or R-CVP (rituximab-cyclophosphamide, vincristine, prednisone) regimens, or in alternative therapy-induced diarrhea, were suggested to explain hypokalemia. In a recent analysis of the American National Cancer Institute, hypokalemia was reported as the most frequent metabolic disturbance after administration of many anticancer targeted therapies, but not rituximab ([@B13]). As an example, treatment with monoclonal antibodies targeting the epidermal growth factor receptor-1 (EGFR-1 or HER-1), like cetuximab and panitumumab, was linked to hypokalemia ([@B14]). In the kidney, EGFR regulates the transport of transient receptor potential melastatin (TRPM) 6/7 ion channels to the apical membrane of the distal renal tubule, thus regulating magnesium reabsorption. By blocking the EGFR, these drugs reduce apical TRPM ion channels, causing renal magnesium wasting and hypomagnesemia which may lead to hypokalemia and cardiac arrhythmias ([@B14]). In one report of pemphigus patients treated with rituximab, an increase in KCNN4 potassium channels on B cell surface has been described ([@B2]). However, B cell KCNN4 channels promote calcium influx in exchange with potassium efflux, not likely being responsible for hypokalemia.

Although limited by being a single case report, and by the impossibility to establish a precise mechanism and causal relationship, the acute, symptomatic, and promptly reversible hypokalemia experienced by our patient suggests, for the first time, a tight link with rituximab infusion. However, an immune-mediated hypersensitivity mechanism underlying the adverse reaction seems not likely. Moreover, the patient was completely fine in the previous days, her nephrotic syndrome was in remission phase, and she wasn\'t taking any other drug. Her magnesium and glucose levels were normal, both excluding a possible link with hypomagnesemia or abrupt hyperinsulinemia. More research data are needed about the action of rituximab on potassium ion channels in order to define the complete landscape of possible interactions. Frequently reported nonspecific symptoms, like palpitations and dizziness, and cardiac complications, like arrhythmias, may potentially be related to undetected hypokalemia. Although never documented in the patient history, we could speculate that acute hypokalemia could explain the symptoms she experienced also after prior infusions, highlighting how such adverse drug reaction, when mild and self-limiting, can easily be overlooked if not expected or investigated.

In conclusion, health professionals should take into account the possibility of acute hypokalemia after rituximab administration in the case of suggestive clinical manifestations, in order to promptly setup the appropriate treatment and avoid potentially serious complications.
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